公开(公告)号：US20250115572A1

公开(公告)日：2025-04-10

申请号：US18729949

申请日：2023-01-20

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Lara C. CZABANIUK ,  Stefanie FLOHR ,  François GESSIER ,  Michael Christoph HEDIGER ,  Konstanze HURTH ,  Nancy LABBE-GIGUERE ,  Fabio LIMA ,  Tajesh PATEL ,  Oliver SIMIC ,  Martin SENDZIK ,  Angela VITREY ,  Anna VULPETTI

IPC: C07D401/06 ,  A61K31/438 ,  A61K31/444 ,  C07D401/14 ,  C07D405/14

Abstract: Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).

公开(公告)号：US20200376129A1

公开(公告)日：2020-12-03

申请号：US16901601

申请日：2020-06-15

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Myriam APRIL ,  Tanzina FAZAL ,  Cornelia Jutta FORSTER ,  Edward Charles HALL ,  Cameron Chuck-munn LEE

IPC: A61K47/36 ,  A61K9/00 ,  A61K31/496 ,  A61P27/02 ,  A61K47/22 ,  A61K47/61 ,  A61K47/69 ,  A61K47/10

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

公开(公告)号：US20230201353A1

公开(公告)日：2023-06-29

申请号：US18054767

申请日：2022-11-11

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Myriam APRIL ,  Tanzina FAZAL ,  Cornelia Jutta FORSTER ,  Edward Charles HALL ,  Cameron Chuck-munn LEE

IPC: A61K47/36 ,  A61K47/61 ,  A61K47/69 ,  A61P27/02 ,  A61K9/00 ,  A61K31/496 ,  A61K47/10 ,  A61K47/22

CPC classification number: A61K47/36 ,  A61K47/61 ,  A61K47/6903 ,  A61P27/02 ,  A61K9/0048 ,  A61K31/496 ,  A61K47/10 ,  A61K47/22

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

公开(公告)号：US20220257596A1

公开(公告)日：2022-08-18

申请号：US17625201

申请日：2020-07-13

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Qian HUANG ,  Sandra TEIXEIRA ,  Brett THIBODEAUX

IPC: A61K31/506 ,  A61K31/405 ,  A61K31/454 ,  A61K31/195 ,  A61K31/497 ,  A61K31/18 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/137 ,  A61K31/496 ,  A61K31/416 ,  A61K31/4545 ,  A61K9/00 ,  A61P27/14

Abstract: The present invention provides methods for treating meibomian gland dysfunction using liver X receptor (LXR) agonists.

公开(公告)号：US20180303945A1

公开(公告)日：2018-10-25

申请号：US15957474

申请日：2018-04-19

Applicant: NOVARTIS AG

Inventor： Christopher M. ADAMS ,  Myriam APRIL ,  Tanzina FAZAL ,  Cornelia Jutta FORSTER ,  Edward Charles HALL ,  Cameron Chuck-munn LEE

IPC: A61K47/36 ,  A61K47/10 ,  A61K47/22 ,  A61K31/496 ,  A61K9/00 ,  A61P27/02

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

公开(公告)号：US20220323595A1

公开(公告)日：2022-10-13

申请号：US17804217

申请日：2022-05-26

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Myriam APRIL ,  Tanzina FAZAL ,  Cornelia Jutta FORSTER ,  Nicole GERWIN ,  Edward Charles HALL ,  Jean-Baptiste Georges Armand LANGLOIS ,  Cameron Chuck-munn LEE

IPC: A61K47/65 ,  A61K47/54 ,  A61K47/69 ,  A61P19/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  C07K14/515

Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

公开(公告)号：US20190119254A1

公开(公告)日：2019-04-25

申请号：US16216420

申请日：2018-12-11

Applicant: NOVARTIS AG

Inventor： Christopher M. ADAMS ,  Doug BEVAN ,  Michael Paul CAPPARELLI ,  Takeru EHARA ,  Luciana FERRARA ,  Nan Ji ,  Erik MEREDITH ,  Muneto MOGI ,  James J. POWERS ,  Ganesh PRASANNA ,  Nello MAINOLFI ,  Mitsunori KATO

IPC: C07D401/14 ,  C07D405/14 ,  A61K31/4545 ,  A61K31/4725 ,  A61K9/00 ,  C07D413/14 ,  A61K31/454 ,  C07D401/12 ,  C07D401/10 ,  A61K31/4439

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.